What question did this study set out to answer?

The main aim is to evaluate the effectiveness and safety of Mitapivat for treating anemia caused by thalassemia.

April 25, 2026

New treatment for anemia secondary to thalassemia

Key Points

The main aim is to evaluate the effectiveness and safety of Mitapivat for treating anemia caused by thalassemia.
Approval process for Mitapivat as a treatment for α- and β-thalassemia.
Assessment of liver functioning through repeat laboratory tests.
Mitapivat is the first oral treatment approved for β-thalassemia.
It is the first drug approved for α-thalassemia.
Boxed warning indicates increased risk of liver damage.

Abstract

Mitapivat (Aqvesme) has been approved to treat anemia in adults with α- or β-thalassemia. It is the first oral treatment for β-thalassemia and the first drug approved to treat α-thalassemia. Mitapivat's labeling carries a boxed warning that it increases the risk of liver damage and requires repeat laboratory tests to assess liver functioning.

Bookmark

Cite This Study

Diane S. Aschenbrenner (Thu,) studied this question.

synapsesocial.com/papers/69ec5b6088ba6daa22dacf56 https://doi.org/https://doi.org/10.1097/ajn.0000000000000297a

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

Bookmark